NewslettersCell Therapy NewsESC & iPSC NewsHuman Immunology NewsPancreatic Cell News Vertex Absorbs ViaCyte and Its Stem Cell-Based Diabetes Treatment for $320M, Clearing Out Competition By Danielle Corrigan - July 12, 2022 0 Just a week after Vertex’s stem cell therapy to treat type 1 diabetes was released from an FDA clinical hold, the company is clearing out potential competition by buying ViaCyte for $320 million. [Fierce Biotech] Press Release